↓ Skip to main content

A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Overview of attention for article published in BMC Cancer, April 2016
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer
Published in
BMC Cancer, April 2016
DOI 10.1186/s12885-016-2234-0
Pubmed ID
Authors

Xiao-Jiang Sun, Qing-Hua Deng, Xin-Min Yu, Yong-Lin Ji, Yuan-Da Zheng, Hao Jiang, Ya-Ping Xu, Sheng-Lin Ma

Abstract

Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in different human cancers. This study assessed the efficacy of endostatin combined with concurrent chemoradiotherapy of non-small cell lung cancer (NSCLC). Nineteen patients with unresectable stage III NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-l, and adequate organ function were treated with 60-66 Gy thoracic radiation therapy over 30-33 fractions concurrent with weekly 7.5 mg/m(2) endostatin for 14 days, 50 mg/m(2) paclitaxel, and 2 mg/mL/min carboplatin over 30 min. Patients were then treated with 7.5 mg/m(2) endostatin for 14 days, 150 mg/m(2) paclitaxel, and 5 mg/mL/min carboplatin every 3 weeks for 2 cycles as the consolidation treatment. The objective response rate was recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and the toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. Six patients were unable to complete the consolidation treatment (4 pulmonary toxicity, 1 tracheoesophageal fistulae, and 1 progressive disease). Seventeen patients were included for data analysis. Specifically, one (5.9 %) patient had a complete response and 12 (70.6 %) had a partial response, whereas two patients had stable disease and the other two had disease progression. The overall response rate was 76 % (95 % confidence interval [CI], 51 %-97 %). The median progression-free survival was 10 months (95 % CI, 7.6-12.3 months), and the median overall survival was 14 months (95 % CI, 10.7-17.2 months). Early 10 patients who completed the treatment regimen showed that four patients experienced grade III pulmonary toxicity a few months after chemoradiotherapy, leading to the early closure of the trial according to the study design. The reslult of concurrent endostatin treatment with chemoradiotherapy in locally advanced unresectable NSCLC did not meet the goal per study design with unacceptable toxicity. The real impact of endostatin as the first-line treatment combined with chemoradiotherapy on the survival of NSCLC patients remains to be determined. (NCT 01158144).

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 19%
Student > Bachelor 4 11%
Student > Master 4 11%
Unspecified 3 8%
Other 2 6%
Other 7 19%
Unknown 9 25%
Readers by discipline Count As %
Medicine and Dentistry 12 33%
Unspecified 3 8%
Nursing and Health Professions 3 8%
Biochemistry, Genetics and Molecular Biology 2 6%
Sports and Recreations 1 3%
Other 3 8%
Unknown 12 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2016.
All research outputs
#5,715,496
of 7,551,260 outputs
Outputs from BMC Cancer
#2,131
of 3,293 outputs
Outputs of similar age
#190,759
of 271,785 outputs
Outputs of similar age from BMC Cancer
#78
of 141 outputs
Altmetric has tracked 7,551,260 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,293 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.